Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2006

View Archived Issues

Snapshots on the antineoplastic effects of farnesyltransferase inhibitors

Degarelix achieves positive phase IIb results, enters phase III development

CRx-119 misses endpoint in exploratory immunoinflammatory disease model

EvoGenix inlicenses anticancer antibody

Genelabs draws up protocol for additional Prestara trial

New phase II study begins for GLP-1 agonist AVE-0010

Praecis enters pilot study and option agreement with GSK

Forest and Almirall sign U.S. agreement for COPD treatment LAS-34273

Enrollment terminated in GENASIS trial

Adventrx and SD Pharmaceuticals sign definitive merger agreement

Pharmacyclics acquires therapeutic programs from Celera Genomics

Quigley to begin clinical studies for QR-333

Pharmos awarded Israeli grant for CB2-selective drug development

BL-1020 for schizophrenia studied in phase I trial

Rufinamide efficacy revealed in partial seizures

Indiplon improves insomnia

Studies evaluate FTY-720 in humans, investigate mechanism of action

Analyses show noninferiority of faropenem antibiotic efficacy

Resistant pneumococcal disease declined after introduction of conjugate vaccine

Bivalent human papillomavirus vaccine provides long-term protection

NXL-101 evaluated in phase I study

Silenor gives statistically significant improvements in wake after sleep onset

Ambrisentan improves exercise capacity in PAH patients

Supplemental BLA submitted for Avastin in NSCLC

Novel 5-HT6 agonists from Wyeth presented at ACS

S1P receptor agonists emerge from Praecis R&D

New treatment strategies for cancer covered in recent patents

Indena synthesizes water-soluble camptothecin analogue with promising profile

Chiron presents preclinical data on its selective Raf kinase inhibitor CHIR-265

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.